A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy

ConclusionART-123 showed a potential preventive effect against OIPN with good tolerability. A larger study with 1-day ART is warranted.NCT02792842, registration date: June 8, 2016
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research